Indication

X-linked hypophosphatemic osteomalacia

X-linked hypophosphatemic osteomalacia is a rare, hereditary metabolic bone disorder representing the adult skeletal manifestation of X-linked hypophosphatemia. Read more about X-linked hypophosphatemic osteomalacia

44 drugs 39 manufacturers

Advertisement

Drugs that treat it

Common X-linked hypophosphatemic osteomalacia therapies.

Showing 1–9 of 44 drugs

Filter & compare in the drug finder →Opens the drug finder with X-linked hypophosphatemic osteomalacia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About X-linked hypophosphatemic osteomalacia.

X-linked hypophosphatemic osteomalacia is a rare, hereditary metabolic bone disorder representing the adult skeletal manifestation of X-linked hypophosphatemia.

It primarily affects skeletally mature adolescents and adults, driven by loss-of-function variants in the *PHEX* gene that lead to excessive circulating fibroblast growth factor 23 (FGF23).

This excess hormone induces renal phosphate wasting and impairs active vitamin D synthesis, resulting in chronic hypophosphatemia and defective mineralization of mature bone matrix.

Clinically, affected patients present with generalized bone pain, persistent muscle weakness, pseudofractures, increased fracture susceptibility, early-onset enthesopathies, and impaired physical mobility.

Personalize your experience

Follow X-linked hypophosphatemic osteomalacia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it